scholarly journals 1246: PHENOBARBITAL VERSUS BENZODIAZEPINES FOR ALCOHOL WITHDRAWAL IN THE INPATIENT SETTING

2021 ◽  
Vol 50 (1) ◽  
pp. 623-623
Author(s):  
Alex Smith ◽  
David Sudekum ◽  
Sarah Kean
Keyword(s):  
Alcohol Withdrawal ◽  
Inpatient Setting

Management of Acute Alcohol Withdrawal in the Inpatient Setting

2001 ◽  
Vol 36 (5) ◽  
pp. 566-573
Author(s):  
Peggy Soule Odegard ◽  
Mikell Goe
Keyword(s):  
Health Care ◽  
Drug Therapy ◽  
Health Care Providers ◽  
Alcohol Withdrawal ◽  
Washington State ◽  
Inpatient Setting ◽  
Care Providers ◽  
Patient Centered ◽  
Drug Therapy Management ◽  
E Mail

Collaborative drug therapy management (CDTM) is a method for developing a patient-centered practice in which the pharmacist's activities are integrated with those of other health care providers. The goals of this continuing feature are to refine the concept of CDTM and provide patient-care applications from the authors' experience in Washington state. Questions or suggestions should be addressed to Timothy S. Fuller, FASHP, Fuller and Associates, 1948 Boyer Avenue East, Seattle, WA 98112-2924 (tel.206-860-8308). E-mail: [email protected]

Pharmacology of Alcohol Use Disorder

2020 ◽  
pp. 203-220
Author(s):  
Megan Lemay
Keyword(s):  
Alcohol Use ◽  
Alcohol Withdrawal ◽  
Alcohol Use Disorder ◽  
Behavioral Treatment ◽  
Treatment Plan ◽  
Medication Management ◽  
Outpatient Setting ◽  
Inpatient Setting ◽  
Standard Medication ◽  
Long Acting

Alcohol use disorder (AUD) is a common and costly disease. Alcohol withdrawal is a common complication of AUD. Alcohol withdrawal has primarily been managed in the inpatient setting, though evidence supports treatment in the outpatient setting for selected low-risk patients. Benzodiazepines are the gold standard medication class to prevent complications of alcohol withdrawal and may be given in symptom-triggered, fixed-schedule, and loading dose regimens. Medications for the treatment of AUD are effective and underutilized. There are three medications approved by the US Food and Drug Administration for AUD: naltrexone (available in short-acting oral and long-acting injectable formulations), acamprosate, and disulfiram. Naltrexone and acamprosate are preferred in most settings due to their efficacy and tolerability. Patients with moderate to severe AUD should be offered medication as part of their treatment plan along with a comprehensive history and physical, behavioral treatment, and mutual goal-setting. It is recommended that medications for AUD are continued for at least 6–12 months or until their risks outweigh their benefits. This chapter reviews the medication management of alcohol withdrawal and AUD in detail.

Measurements of change during alcohol withdrawal in chronic alcoholics.

1970 ◽  
Author(s):  
J. Allan Burdick ◽  
Laverne C. Johnson ◽  
James W. Smith
Keyword(s):  
Alcohol Withdrawal

Wellness and Recovery in the Inpatient Setting: Developing a Wellness Card

2012 ◽  
Author(s):  
Niamh Casey ◽  
◽  
Christine O'Byrne ◽  
Sharon McCaffrey
Keyword(s):  
Inpatient Setting

Changes in visual evoked potentials following alcohol withdrawal

1976 ◽  
Author(s):  
Henri Begleiter ◽  
Bernice Porjesz ◽  
Benjamin Kissin
Keyword(s):  
Evoked Potentials ◽  
Visual Evoked Potentials ◽  
Alcohol Withdrawal ◽  
Visual Evoked

Early recovery following traumatic brain injury and alcohol withdrawal management.

2018 ◽  
Vol 63 (4) ◽  
pp. 588-594
Author(s):  
Daniel W. Klyce ◽  
Kristin M. Graham ◽  
Russell W. Lacey ◽  
William E. Carter
Keyword(s):  
Traumatic Brain Injury ◽  
Brain Injury ◽  
Alcohol Withdrawal ◽  
Early Recovery ◽  
Withdrawal Management
Sign in / Sign up

Export Citation Format

Share Document